Posted by Michael Wonder on 17 May 2016
CADTH publishes final report for anti–vascular endothelial growth factor drugs for retinal conditions
17 May 2016 - The recommendations report is now available for the CADTH project on anti–vascular endothelial growth factor drugs for retinal conditions.
As the Canadian population ages, retinal conditions are likely to be increasingly encountered in clinical practice. Drugs acting on a protein called vascular endothelial growth factor (VEGF) have been shown to be effective in the treatment of these conditions. Whether the use of different anti-VEGF drugs results in important clinical differences is unclear.
CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) that are commonly used to treat the following retinal conditions: age-related macular degeneration, choroidal neovascularization, diabetic macular oedema, pathologic myopia and retinal vein occlusion. The therapeutic review project includes a science report (clinical and economic evaluations) and a recommendations report.
